Condition category
Infections and Infestations
Date applied
01/03/2019
Date assigned
02/04/2019
Last edited
02/04/2019
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
The aim of the study was to evaluate the effect of the vaginal application of the Papilocare® gel on different aspects related to your vaginal health, among others, on the regeneration of the cervical mucosa and the state of the vaginal flora, of women with presence of human papillomavirus, but no lesion visible on colposcopy.

Who can participate?
Sexually active women, 25 years of age and older, attending a routine control gynecologic visit, infected with human papillomavirus but with normal results in cytology and colposcopy.

What does the study involve?
All participants received the same treatment, Papilocare, a non-hormonal vaginal gel once daily for 21 consecutive days, preferably at bedtime

What are the possible benefits and risks of participating?
Possible benefits: improving both the regeneration of the cervical mucosa and the state of the vaginal flora. These effects improve your vaginal health.

No important risks were expected.

Where is the study run from?
Service of Gynaecology, Policlínico HM Gabinete Velázquez, Madrid, Spain. Vagina flora samples were evaluated in CIBER-EHD, Department of Pharmacology, University of Granada, Spain.

When is the study starting and how long is it expected to run for?
July 2016 to January 2017.

Who is funding the study?
Work time dedicated to this study by University of Granada personnel falls within funds from Regional Government of Andalucía and by the Spanish Ministry of Economy and Competitiveness with funds from the European Union.

Procare Health SL (Castelldefels, Barcelona, Spain), owner of Papilocare provided logistic support for the study but had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Who is the main contact?
Julio Galvez
jgalvez@ugr.es

Trial website

N/A

Contact information

Type

Scientific

Primary contact

Prof Maria Elena Rodriguez-Cabezas

ORCID ID

http://orcid.org/0000-0001-9085-8147

Contact details

Centre for Biomedical Research
University of Granada
Avenida del Conocimiento s/n
Granada
18016
Spain
+34-958-241793
merodri@ugr.es

Additional identifiers

EudraCT number

N/A

ClinicalTrials.gov number

N/A

Protocol/serial number

EPI001

Study information

Scientific title

Effect of a Coriolus versicolor-based vaginal gel on cervical epithelization and vaginal microbiota in HPV-positive women with normal cytology and colposcopy: a pilot study

Acronym

Epicervix

Study hypothesis

Evaluating the impact of the non-hormonal vaginal gel Papilocare® on cervical epithelization and the composition of vaginal microbiota in HPV-positive women with normal cytology and colposcopy.

Ethics approval

Approval of the study protocol by the institutional review board was not required because according to the Spanish law (Real Decreto 1591/2009, de 16 de octubre, por el que se regulan los productos sanitarios. Ministerio de Sanidad y Política Social «BOE» núm. 268, de 6 de noviembre de 2009 Referencia: BOE-A-2009-17606. TEXTO CONSOLIDADO. Última modificación: 25 de julio de 2013), studies with a medical device class I (not a drug) already marketed and used within approval indications are exempted.

Study design

A non-comparative, open-label, prospective, and pilot study

Primary study design

Observational

Secondary study design

Cohort study

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

See additional file.

Condition

Human papillomavirus infection

Intervention

Women who gave consent to participate in the study and met the inclusion criteria were advised on the appropriate use of the vagina gel product Papilocare®. Participants were visited at baseline (screening) (visit 1, inclusion in the study) and after 21 days of treatment (visit 2). In both visits, the degree of epithelization was assessed by colposcopy and samples were obtained to determine the composition of the vaginal microbiota. Recruitment period started in July 2016. The total duration of the study was from July 2016 to January 2017.

Intervention type

Device

Phase

Not Applicable

Drug names

Primary outcome measure

The epithelization degree of the cervical mucosa was assessed by the investigator by standard colposcopy and rated using a 5-point Likert scale, where 5 was no ectopy, 4: mild (<25% of the external os), 3: moderate (25–50% of the external os), 2: severe (>50% of the external os) and 1: severe ectopy and bleeding. This variable was measured at baseline and 21 days.

Secondary outcome measures

The composition of bacterial communities was assessed by calculating three major ecological parameters, including the Chao1 richness index for abundance data (an estimate of a total community), the Pielou’s evenness index (to show how evenly the individuals in the community were distributed over different operational taxonomic units [OUT]) , and the Shannon biodiversity index (a combined parameter of richness and evenness) [34]. The Shannon biodiversity index was categorized as < 2 (low diversity), 2-3 (normal), and > 3 (high diversity). This variable was measured at baseline and 21 days.

Overall trial start date

01/07/2016

Overall trial end date

31/01/2017

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

1. Sexually active women
2. 25 years of age and older
3. Attending a routine control gynecologic visit
4. Normal Papanicolaou smear and normal colposcopic findings
5. Diagnosis of HPV positivity by polymerase chain reaction (PCR)-based HPV DNA detection within 3 months before consultation.

Participant type

Patient

Age group

Adult

Gender

Female

Target number of participants

21 women

Total final enrolment

21

Participant exclusion criteria

1. Clinically relevant disorders of the immune system
2. Treatment with immunosuppressant agents
3. Abnormal vaginal bleeding (without diagnosis) within the 6 months prior to the screening visit
4. Symptomatic vulvovaginal infection
5. History of gynecologic cancer
6. Use of vaginal contraceptives or other vaginal hormonal treatments
7. Planned surgery preventing compliance with treatment
8. Current participation in a current clinical trials or in the previous 4 weeks
9. Fertile women not using effective contraceptive methods
10. Pregnant or breastfeeding
11. Contraindication for the use of Papilocare® or known allergies to some of its components.

Recruitment start date

10/07/2016

Recruitment end date

05/01/2017

Locations

Countries of recruitment

Spain

Trial participating centre

Service of Gynecology, Policlínico HM Gabinete Velázquez
orge Juan Street, 19 - 1 ° , 28001 Madrid
Madrid
28001
Spain

Sponsor information

Organisation

Gabinete Médico Velázquez SL

Sponsor details

Jorge Juan Street
19 - 1 °
Madrid
28001
Spain
915 77 77 73
silviapgonzalez@yahoo.es

Sponsor type

Hospital/treatment centre

Website

http://www.gabinetemedicovelazquez.com/index.php/en/#

Funders

Funder type

Government

Funder name

Ministerio de Economía y Competitividad

Alternative name(s)

Ministry of Economy and Competitiveness, MEC, MINECO

Funding Body Type

government organisation

Funding Body Subtype

National government

Location

Spain

Funder name

Junta de Andalucía

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

We plan to publish the results in the BMC Women's Health Journal.

IPD sharing statement: the datasets generated during and/or analysed during the current study are not expected to be made available as patient names were included in the dataset.

Intention to publish date

20/07/2019

Participant level data

Not expected to be available

Basic results (scientific)

N/A

Publication list

N/A

Publication citations

Additional files

Editorial Notes

29/03/2019: Trial's existence confirmed by Procare Health Iberia, S.L.